Ποια είναι η τιμή για Redx Pharma Plc (REDX)

Η τιμή για Redx Pharma Plc (REDX) είναι $0.20410523

Ποια είναι η κεφαλαιοποίηση αγοράς για Redx Pharma Plc (REDX)

Η κεφαλαιοποίηση αγοράς για Redx Pharma Plc (REDX) είναι $793.94K

Redx Pharma Plc (REDX) Κέρδη

Redx Pharma Plc, established in the United Kingdom in 2010 and headquartered in Macclesfield, concentrates its efforts on the discovery, early-stage preclinical development, and licensing of innovative small molecule drugs. The company primarily targets significant unmet medical needs in the therapeutic areas of oncology and fibrosis. Within its oncology portfolio, Redx is progressing RXC004, a porcupine inhibitor currently undergoing Phase II clinical evaluation for treating cancers driven by Wnt-ligands. Additionally, it maintains a research collaboration with Jazz Pharmaceuticals plc, aiming to identify and advance new drug candidates for two specific cancer pathways: the Ras/Raf/MAP kinase pathway. For fibrotic conditions, Redx Pharma is developing several compounds, including RXC007, an oral selective ROCK2 inhibitor intended for the treatment of various fibrotic diseases. Its pipeline also features a gastrointestinal-targeted ROCK inhibitor specifically designed to address fibrosis associated with Crohn's disease, along with a discoidin domain receptors (DDRs) inhibitor for a range of fibrotic disorders. Furthermore, the company is developing RXC006, another porcupine inhibitor, focused on combating fibrotic illnesses such as idiopathic pulmonary fibrosis.

Έτος	Κέρδη	Αλλαγή
Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Έτος

Κέρδη

Αλλαγή

Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Εταιρεία	Κέρδη	Διαφορά Κερδών	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$3.01B	-	BE

Εταιρεία

Κέρδη

Διαφορά Κερδών

Χώρα